Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
SLC6A2 6530 MAZINDOL CHEMBL781 inhibitor GuideToPharmacologyInteractions, DrugBank 12885787, 2120386, 10966747, 9537821, 16954558, 15300361
SLC6A2 6530 PHENMETRAZINE CHEMBL1201208 inhibitor TdgClinicalTrial, TEND, DrugBank 17017961, 17139284, 17016423, 12106802
SLC6A2 6530 CHLORPHENIRAMINE POLISTIREX CHEMBL1201659 inhibitor DrugBank 9537821
SLC6A2 6530 MIANSERIN CHEMBL6437 inhibitor DrugBank 9537821
SLC6A2 6530 TAPENTADOL CHEMBL1201776 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank 17656655
SLC6A2 6530 AMITRIPTYLINE CHEMBL629 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 ATOMOXETINE CHEMBL641 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 CITALOPRAM CHEMBL549 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 CLOMIPRAMINE CHEMBL415 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 DESVENLAFAXINE CHEMBL1118 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 DOTHIEPIN (CHEMBL1492500) CHEMBL1492500 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 DULOXETINE CHEMBL1175 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 LOFEPRAMINE CHEMBL87708 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 MAPROTILINE CHEMBL21731 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 MILNACIPRAN CHEMBL259209 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 NISOXETINE CHEMBL295467 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 PROTRIPTYLINE CHEMBL668 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 [3H]NISOXETINE CHEMBL1628648 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 PSEUDOEPHEDRINE CHEMBL1590 TdgClinicalTrial
SLC6A2 6530 AMOXAPINE CHEMBL1113 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 9537821, 17139284, 17016423
SLC6A2 6530 ERGOTAMINE CHEMBL442 inhibitor DrugBank 17139284, 17016423
SLC6A2 6530 COCAINE CHEMBL370805 inhibitor TdgClinicalTrial, TEND, DrugBank 7500004, 9387868, 15351386, 15113605
SLC6A2 6530 CHEMBL126506 CHEMBL126506 negative modulator DrugBank 17209801
SLC6A2 6530 METHAMPHETAMINE CHEMBL1201201 negative modulator TdgClinicalTrial, DrugBank 17209801, 15955613
SLC6A2 6530 NOMIFENSINE CHEMBL273575 inhibitor GuideToPharmacologyInteractions, DrugBank 9537821
SLC6A2 6530 AMINEPTINE CHEMBL418995 DrugBank 17139284, 17016423
SLC6A2 6530 LEVOMILNACIPRAN CHEMBL99946 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank
SLC6A2 6530 DOXEPIN CHEMBL1628227 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 NEFAZODONE CHEMBL623 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 PHENELZINE CHEMBL1089 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 QUETIAPINE CHEMBL716 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 BETHANIDINE CHEMBL1201260 TdgClinicalTrial, TEND
SLC6A2 6530 TRAMADOL CHEMBL1237044 TdgClinicalTrial, TEND
SLC6A2 6530 DEXMETHYLPHENIDATE CHEMBL827 TdgClinicalTrial
SLC6A2 6530 REBOXETINE CHEMBL14370 inhibitor GuideToPharmacologyInteractions, DrugBank 16633143, 12623106, 11249515, 16893531, 12388649, 15878511
SLC6A2 6530 MIRTAZAPINE CHEMBL654 binder DrugBank 15771415, 9537821
SLC6A2 6530 METHYLENEDIOXYMETHAMPHETAMINE CHEMBL43048 negative modulator DrugBank 17209801, 15955613, 10773193
SLC6A2 6530 BUPROPION CHEMBL894 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 DESIPRAMINE CHEMBL72 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 DEXTROAMPHETAMINE CHEMBL612 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions
SLC6A2 6530 ZOTEPINE CHEMBL285802 inhibitor GuideToPharmacologyInteractions
SLC6A2 6530 EDIVOXETINE CHEMBL2103857 TdgClinicalTrial
SLC6A2 6530 PHENTERMINE CHEMBL1574 TdgClinicalTrial, TEND
SLC6A2 6530 CHEMBL488638 CHEMBL488638 TdgClinicalTrial
SLC6A2 6530 TEDATIOXETINE CHEMBL2104986 TdgClinicalTrial
SLC6A2 6530 AMPHETAMINE CHEMBL405 stimulator DrugBank 12954796, 7700252
SLC6A2 6530 GUANADREL CHEMBL1037 partial agonist DrugBank 6351026, 17139284, 17016423, 6850722, 3896742
SLC6A2 6530 LOXAPINE CHEMBL831 binder DrugBank
SLC6A2 6530 SIBUTRAMINE CHEMBL1419 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 18671470, 17284621, 10929704, 19475780, 11752352, 11152984, 12417543, 15685250, 15944869, 15382615, 16678551
SLC6A2 6530 GUANETHIDINE CHEMBL765 inducer TdgClinicalTrial, TEND, DrugBank 16126010, 11403930, 8710929
SLC6A2 6530 CHEMBL528995 CHEMBL528995 TdgClinicalTrial
SLC6A2 6530 DEBRISOQUIN CHEMBL169901 inducer DrugBank 5431666, 12401623, 16126010, 8710929, 8740147
SLC6A2 6530 IMIPRAMINE CHEMBL11 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 METHYLPHENIDATE CHEMBL796 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 NORTRIPTYLINE CHEMBL445 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 TRIMIPRAMINE CHEMBL644 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 VENLAFAXINE CHEMBL637 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A2 6530 CHEMBL1188853 CHEMBL1188853 TdgClinicalTrial
SLC6A2 6530 AMITIFADINE CHEMBL592374 TdgClinicalTrial
SLC6A2 6530 DIETHYLPROPION CHEMBL1194666 TdgClinicalTrial, TEND
SLC6A2 6530 GUANADREL SULFATE CHEMBL1200594 TdgClinicalTrial, TEND
SLC6A2 6530 TRAZODONE CHEMBL621 TEND
SLC6A2 6530 CHEMBL1079460 CHEMBL1079460 inhibitor TTD
SLC6A2 6530 TESOFENSINE CHEMBL2107788 TdgClinicalTrial
SLC6A2 6530 GINKGO CHEMBL2108466 inhibitor DrugBank 19427589
SLC6A2 6530 BICIFADINE CHEMBL511099 DrugBank 17325229

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
SLC6A2 rs5569 GG methylphenidate efficacy yes Compared the response of MPH between the patients with G/G genotype and those without G/G genotype, 41 (71.9%) patients with G/G genotype showed good response, whereas only 27 (46.4%) patients without G/G genotype showed good response (P=0.008). Association found for both ADHD rating scale-IV scores or Clinical Global Impression-Severity scores. Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. 21127421 827809082
SLC6A2 rs3785143 T atomoxetine efficacy yes The T allele was associated with being a non-responder to atomoxetine treatment. Children were given the drug for 8 - 12 weeks. Response was defined as at least a 25% decrease from baseline on the ADHD-RS-IV total score. No association was seen with remission. Multiple test correction still gave a significant p-value (p=0.0416). Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 23266789 1184165220
SLC6A2 rs28386840 AT + TT methylphenidate efficacy yes Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. 29230023 1450180215
SLC6A2 rs5569 GG methylphenidate efficacy yes Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. 29230023 1450180222
SLC6A2 rs5569 AG + GG methylphenidate efficacy yes Post hoc least significant difference comparisons suggested that subjects with both G/G and G/A genotypes showed greater symptom reductions (7.15 ± 4.25 and 6.94 ± 5.60) than those with A/A genotypes (2.13 ± 4.29) (p < .01). Response was measured using the ADHD RS-IV scale. Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. 15322419 1450376330
SLC6A2 rs5569 GG methylphenidate efficacy no ADHD Rating Scale-IV (ADHD-RS) total score was used to assess response. Independent associations of genotype with MPH response based on Fisher's exact tests are also described, and only the norepinephrine transporter polymorphism showed a trend of association. Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. 23083021 1450376345
SLC6A2 rs28386840 AT + TT methylphenidate efficacy yes ADHD Rating Scale-IV (ADHD-RS) total score was used to assess response. Independent associations of genotype with MPH response based on Fisher's exact tests are also described, and only the norepinephrine transporter polymorphism showed a significant association. Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. 23083021 1450376358
SLC6A2 rs28386840 AT + TT methylphenidate efficacy not stated ADHD Rating Scale-IV (ARS) and Clinical Global Impression (CGI) were used to assess response. Of the subjects who had the T allele as one of the alleles (A/T or T/T genotypes) at the -3081(A/T) polymorphism, 61.4% (51 of 83) showed a good response (CGI-I = 1 or 2) to MPH treatment. However, only 37.9% (11 of 29) of the subjects with the A/A genotype showed a good response to MPH treatment (p = 0.03) = trend of significance. Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. 20929549 1450376384
SLC6A2 rs5569 GG methylphenidate efficacy no ADHD Rating Scale-IV (ARS) and Clinical Global Impression (CGI) were used to assess response. Genotype GG is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. 20929549 1450376393
SLC6A2 rs28386840 AT + TT methylphenidate efficacy not stated After 8 weeks of treatment, subjects with the A/A genotype at the A-3081T polymorphism showed less improvement in the mean commission error scores (p = 0.003) than those with the A/T or T/T genotypes. Subjects with the T/T genotype showed the greatest decrease in commission errors, followed by the A/T genotype and A/A genotype (p = 0.007). Test of variables of attention (TOVA) described as continuous performance test (CPT). Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. 22591463 1450376406
SLC6A2 rs5569 GG methylphenidate efficacy not stated After 8 weeks of treatment with methylphenidate, subjects with the G/ G genotype at the G1287A polymorphism showed more improvement in the mean omission error scores (p = 0.006) than those with the A/G or A/A genotypes. Subjects with the G/G genotype showed the greatest decrease in omission errors. Test of variables of attention (TOVA) described as continuous performance test (CPT). Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. 22591463 1450376415
SLC6A2 rs28386840 AT + TT methylphenidate efficacy no With MPH-response only the promoter rs28386840 showed nominal association: Those with at least one T-allele were overrepresented in the responder group (42% vs 19%, p=0.08), and they had better improvement on the hyperactivity-impulsivity scale compared to the AA genotype (p=0.04). Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. 29374517 1450376455
SLC6A2 rs5569 AA + AG methylphenidate efficacy no could detect only tendentious association (0.05 < p < 0.1) at rs28386840 (-3081 A/T SNP) and rs5569 (1287 A/G SNP from exon 9) for the genotype frequencies between responder and non-responder. Genotypes AA + AG are associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG. 29374517 1450376462
SLC6A2 rs28386840 AT + TT methylphenidate efficacy no Meta-analyses of NET SNPs in MPH-response among ADHD patients using genotype-wise data yielded the following values: OR (with upper and lower limit): 2.329 (0.868 – 6.253), z = 1.678, p = 0.093 at rs28386840. Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. 29374517 1450376471
SLC6A2 rs5569 AA + AG methylphenidate efficacy no Meta-analyses of NET SNPs in MPH-response among ADHD patients using genotype-wise data yielded the following values: OR: 0.838 (0.425 – 1.651), z = -0.512, p = 0.609 at rs5569. Genotypes AA + AG are associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG. 29374517 1450376478
SLC6A2 rs2242446 C methylphenidate efficacy no Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T. 29374517 1450376486
SLC6A2 rs3785143 T methylphenidate efficacy no Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 29374517 1450376493
SLC6A2 rs3785157 T methylphenidate efficacy no Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 29374517 1450376500
SLC6A2 rs7194256 T methylphenidate efficacy no Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 29374517 1450376506
SLC6A2 rs5569 G methylphenidate efficacy no After MPH treatment, no significant associations were found between the change in ARS score (ADHD Rating Scale IV = symptom severity scale) and genotype of the 4 SNPs in this study. Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A. 23609393 1450376514
SLC6A2 rs28386840 A methylphenidate efficacy no After MPH treatment, no significant associations were found between the change in ARS score (ADHD Rating Scale IV = symptom severity scale) and genotype of the 4 SNPs in this study. Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T. 23609393 1450376533
SLC6A2 rs28386840 T methylphenidate efficacy no Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS). Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A. 28871191 1450376573
SLC6A2 rs5569 G methylphenidate efficacy no Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS). Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A. 28871191 1450376581
SLC6A2 rs2242446 C methylphenidate efficacy no Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele T. 20863575 981481765
SLC6A2 rs5569 GG antidepressants efficacy no Genotype GG is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG. 23733030 982028745
SLC6A2 rs5569 A clomipramine efficacy no Allele A is not associated with response to clomipramine in people with Obsessive-Compulsive Disorder as compared to allele G. 21625751 827827767
SLC6A2 rs998424 A methylphenidate efficacy no Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G. 20863575 981481795
SLC6A2 rs5569 A methylphenidate efficacy no Allele A is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G. 20863575 981481784
SLC6A2 rs5568 C methylphenidate efficacy no Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A. 20863575 981481774
SLC6A2 rs12708954 A atomoxetine efficacy yes Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 19387424 1183685564
SLC6A2 rs5564 A Selective serotonin reuptake inhibitors efficacy no Reported as C and T reverse strand. Compares association with 3 genotypes and 2 alleles with response and found no association in either case. Allele A is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G. 25642918 1447679428
SLC6A2 rs1362621 A Selective serotonin reuptake inhibitors efficacy no Compares association with 3 genotypes and 2 alleles with response and found no association in either case. Allele A is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G. 25642918 1447679410
SLC6A2 rs2242446 C Selective serotonin reuptake inhibitors efficacy no Compares association with 3 genotypes and 2 alleles with response and found no association in either case. Allele C is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele T. 25642918 1447679420
SLC6A2 rs2242446 CC venlafaxine efficacy yes Response assessed as remission, defined as MADRS score =<10 at the end of treatment. Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT. 28068779 1448601802
SLC6A2 rs36029 AA 3,4-methylenedioxymethamphetamine other yes The AA genotype was associated with increased mean arterial pressure, but not plasma concentrations , or heart rate. Genotype AA is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AG + GG. 29198060 1449160237
SLC6A2 rs168924 G 3,4-methylenedioxymethamphetamine other no Allele G is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A. 29198060 1449160191
SLC6A2 rs47958 C 3,4-methylenedioxymethamphetamine other no Allele C is not associated with response to 3,4-methylenedioxymethamphetamine as compared to allele A. 29198060 1449160206
SLC6A2 rs2242446 TT 3,4-methylenedioxymethamphetamine other yes The TT genotype was associated with decreased heart rate, but not plasma concentrations , or mean arterial pressure. Genotype TT are associated with decreased response to 3,4-methylenedioxymethamphetamine as compared to genotypes CC + CT. 29198060 1449160225
SLC6A2 rs1861647 GG 3,4-methylenedioxymethamphetamine other yes The GG genotype was associated with increased heart rate, but not with plasma concentrations nor mean arterial pressure. Genotype GG is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AA + AG. 29198060 1449160218
SLC6A2 rs5569 G methylphenidate efficacy no Scales used to assess response: ADHD-RS-IV, SWAN, and Permanent productMeasure of Performance (PERMP). Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A. 19858760 1450376338